Overview

A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and pharmacokinetics of Valcyte syrup in pediatric solid organ transplant recipients. The anticipated time on study treatment is 3-12 months and the target sample size is less than 100 individuals.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Ganciclovir
Valganciclovir